Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Gastro Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Gastro Other
    Everolimus Is an Effective Treatment Option for Patients With Pancreatic Neuroendocrine Tumours: Presented at ESMO-GI - (DGDispatch)
    Proton Pump Inhibitors May Increase Risk for Clostridium difficile Outbreaks: Presented at ICC - (DGDispatch)
    Efficacy of Vaccination Against Traveller's Diarrhoea: Presented at ESPID - (DGDispatch)
    CT Colonography May Help High-Risk Patients Adhere to Follow-up Screening - (DGNews)
    Sevelamer Carbonate Approved in EU for Patients With Chronic Kidney Disease - (DGNews)

    News archive

     Recent webcasts/CME - Gastro Other
    • Biologics in Crohn's Disease: Treating Early, Treating Long-Term
    • Long-Term Sustainability Using Biologics in Crohn's Disease
    • Recent Updates in Crohn's Disease: Optimising Remission, Healing, and Quality of Life
    • Advances in the Management of Postoperative Ileus: Reducing the Clinical and Economic Burden
      Irritable Bowel Syndrome with Constipation (IBS-C): Improving Patient Care Assessment and Management

      Webcasts/CME archive

       Recent cases - Gastro Other
        An Unexpected Cause of Iron Deficiency Detected by Capsule Endoscopy
        Acute Abdominal Pain in a Patient Receiving Enoxaparin
        Splenic Rupture Following Colonoscopy, A Rare Complication
        Accurate Localization of Life Threatening Colonic Hemorrhage During Nuclear Medicine Bleeding Scan as an Aid to Selective Angiography
        Disabling Osteomalacia and Myopathy as the Only Presenting Features of Celiac Disease: A Case Report

        Cases archive
          




        my personal edition > gastro other > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Rifabutin Rescue Therapy Effective After Helicobacter Eradication Failures

        A DGReview of :"'Rescue' Therapy with Rifabutin after Multiple Helicobacter pylori Treatment Failures"
        Helicobacter

        04/16/2003
        By David Loshak


        Rescue therapy based on the anti-mycobacterial drug rifabutin offers an "encouraging" rescue therapy after other agents have failed to eradicate Helicobacter pylori.

        A rifabutin-based combination is a promising strategy after such key antibiotics as amoxicillin, clarithromycin, metronidazole and tetracycline have not countered the organism, report gastroenterological researchers in Madrid, Barcelona and Baracaldo, Spain. They pointed out that although eradication therapy using a proton pump inhibitor, clarithromycin or amoxicillin was widely used, it did often fail.

        Rescue therapy combining omeprazole, bismuth, tetracycline and metronidazole (or ranitidine bismuth citrate with these same antibiotics) had been recommended but even this did not work in a fifth of cases. The researchers, therefore, used a prospective multi-centre study to evaluate the efficacy and tolerability of a rifabutin-based regimen in 14 patients who had experienced consecutive H. pylori eradication failures on those two regimens. The patients were aged 42 ± 11 years, six were men. Eight patients had peptic ulcer and six had dyspepsia. All completed the study protocol.

        This third eradication regimen consisted of twice-daily rifabutin 150 mg. amoxicillin 1.0 gram and omeprazole 20 mg. for 14 days. All drugs were administered together after breakfast and dinner.

        Adherence to therapy was determined from questioning patients and from the recovery of empty envelopes of medications.
        The researchers defined H. pylori eradication as a negative 13C-urea breath test eight weeks after completing the treatment.

        Per-protocol and intention-to-treat eradication was achieved in 11 cases. Five had adverse effects such as abdominal pain, nausea and vomiting and oral candidiasis but none stopped treatment as a result.


        http://www.docguide.com/news/content.nsf/WebOpenPaper_TopAbstracts"OpenAgent&newsid=8525697700573E1885256CF90036565E" 'Rescue' Therapy with Rifabutin after Multiple Helicobacter pylori Treatment Failures 2003-03-31 Helicobacter
        Helicobacter 2003;8:2:90-94. "'Rescue' Therapy with Rifabutin after Multiple Helicobacter pylori Treatment Failures"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send